Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | -2325.4% | -992.7% |
ROCE | n/a |
Latest | F'cast | |
---|---|---|
P/E | n/a | n/a |
PEG | n/a | n/a |
Pr/Revenue | 36.3 | 18.2 |
Pr/Book | 0.9 |
Latest | F'cast | |
---|---|---|
Revenue | 2.8% | 99.9% |
PBT | n/a | n/a |
EPS | n/a | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Apr-19 | 0.68 | (10.87) | (6.56)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-19 | 0.58 | (9.04) | (6.88)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-20 | 0.76 | (13.74) | (6.52)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-21 | 1.01 | (17.36) | (6.67)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-22 | 1.04 | (24.44) | (8.97)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-23 | 2.08 | (20.65) | (7.46)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-24 | 6.67 | (13.97) | (4.92)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-25 | 15.00 | (11.00) | (3.66)p | n/a | n/a | n/a | n/a | 0.0% |
Copyright © 2024 FactSet Research Systems Inc. All rights reserved.
New commercial agreement with AstraZeneca | 24-Apr-2024 | 07:00 | RNS |
US and EU patents for innovative CellKeep™... | 22-Apr-2024 | 07:00 | RNS |
Standard form for notification of major holdings | 10-Jan-2024 | 12:57 | RNS |
New Angle for Braveheart | 26-Jan-2009 | The Scotsman |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 14.50p |
Change Today | 0.50p |
% Change | 3.57 % |
52 Week High | 31.40p |
52 Week Low | 9.25p |
Volume | 1,310,616 |
Shares Issued | 260.58m |
Market Cap | £37.78m |
RiskGrade | 312 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 1 |
Buy | 0 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
17:06 | 45,000 @ 14.50p |
16:29 | 50,000 @ 14.25p |
16:24 | 10,000 @ 14.40p |
16:08 | 28,151 @ 14.10p |
16:07 | 28,381 @ 14.00p |
CEO | Andrew D Newland |
Finance Director | Ian F Griffiths |
Chair | Jan Groen |
You are here: research